Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic associations with drug response, pharmacogenetic testing has not been widely implemented into clinical practice. Among the barriers to broad implementation are limited guidance for how to successfully integrate testing into clinical workflows and limited data on outcomes with pharmacogenetic implementation in clinical practice. The Pharmacogenomics Global Research Network Implementation Working Group seeks to engage institutions globally that have implemented pharmacogenetic testing into clinical practice or are in the process or planning stages of implementing testing to collectively disseminate data on implementation strategies, metrics, and health-related outcomes with the use of genotype-guided drug therapy to ultimately help advance pharmacogenetic implementation. This paper describes the goals, structure, and initial projects of the group in addition to implementation priorities across sites and future collaborative opportunities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664750 | PMC |
| http://dx.doi.org/10.1097/FPC.0000000000000547 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics - An evidence-based overview for decision makers.
Aust N Z J Psychiatry
September 2025
Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Melbourne, VIC, Australia.
Psychotropic pharmacogenetics (PGx) offers significant potential advancements in psychiatric care by optimising medication selection and dosing based on genetic factors. This perspective article highlights the clinical utility, health economic implications and implementation challenges of psychotropic PGx, proposing that its broader implementation could enhance patient outcomes and reduce healthcare costs. Landmark studies show that PGx-guided care results in fewer adverse drug reactions and improved medication efficacy, with substantial cost savings compared to traditional prescribing methods.
View Article and Find Full Text PDFExtracting Clinical Guideline Information Using Two Large Language Models: Evaluation Study.
J Med Internet Res
September 2025
Artificial Intelligence Center, China Medical University Hospital, 2, Yude Road, Taichung, 404327, Taiwan, 886 4-22052121.
Background: The effective implementation of personalized pharmacogenomics (PGx) requires the integration of released clinical guidelines into decision support systems to facilitate clinical applications. Large language models (LLMs) can be valuable tools for automating information extraction and updates.
Objective: This study aimed to assess the effectiveness of repeated cross-comparisons and an agreement-threshold strategy in 2 advanced LLMs as supportive tools for updating information.
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider.
Br J Clin Pharmacol
September 2025
Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy.
Aims: Pharmacogenetic implementation requires awareness of the state-of-the-art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco-scheme established since 2019 by the European Molecular genetics Quality Network (EMQN).
Methods: Anonymized clinical pharmacogenetic reports submitted by Italian laboratories participating in the EMQN Pharmaco-scheme between 2019 and 2023 were analysed.
Precision medicine on a budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs.
Front Bioinform
August 2025
Yemaachi Biotech, Accra, Ghana.
Variations in drug-metabolizing enzymes and transporters are associated with adverse drug reactions (ADRs). ADRs to cancer drugs can differ among populations owing to environmental and genetic differences. Due to limited resources and prohibitive costs associated with drug development, African countries rely on cancer drugs developed from non-African genetic backgrounds.
View Article and Find Full Text PDFThe Role of Pharmacogenetic Biomarkers in Pain.
Biomedicines
August 2025
Pharmacy Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
: Pain-whether acute, chronic, or neuropathic-remains a leading cause of disability and reduced quality of life worldwide. Despite advances in pharmacologic options, interindividual variability in response and susceptibility to adverse effects continues to challenge clinicians. In recent years, pharmacogenetics has emerged as a promising approach to optimize analgesic selection and dosing based on patient-specific genetic profiles.
View Article and Find Full Text PDF